MedPath

Maternal and fetal/neonatal pharmacokinetics and - dynamics of corticosteroids during pregnancy as treatment for fetal lung maturatio

Phase 4
Recruiting
Conditions
premature contractions
Preterm birth
10010273
Registration Number
NL-OMON56400
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
400
Inclusion Criteria

1) Older than 18 years of age.
2) Admitted at the Department of Obstetrics at Erasmus MC - Sophia for
suspicion of preterm birth with a gestational age of 23+5 weeks until 33+6
weeks.
3) Understanding of Dutch in speaking and reading.
4) Written informed consent.

In order for the neonate to be able to participate in this study, the parent
must meet the following criteria:
5) Older than 18 years of age.
6) Admitted at the Department of Obstetrics at Erasmus MC - Sophia for
suspicion of preterm birth with a gestational age of 23+5 weeks until 33+6
weeks.
7) Understanding of Dutch in speaking and reading.
8) Written informed consent for the neonate.

Exclusion Criteria

1) Women unable or unwilling to agree with the procedures.
2) Women unable or unwilling to give written informed consent.
3) Women with acute obstetric complications requiring immediate delivery at
time of admission.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>To examine the maternal and fetal (as measured in umbilical cord blood sampling<br /><br>directly after birth) pharmacokinetics of standard regimen at the Erasmus MC of<br /><br>two doses of 12 mg betamethasone intramuscular with a 24 hours interval for<br /><br>pregnant women suspected of preterm birth with a gestational age between 23+5<br /><br>until 33+6 weeks. Farmacokinetic parameters, which will be determined are:<br /><br>distribution (VD), clearance (Cl), elimination-rate constant (kel),<br /><br>steady-state concentration (Css), half-life (t1/2), bioavailability (F).</p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath